Global COVID Testing Kit Research Report—Forecast till 2027
出 版 商：Market Research Future
出版日期：2020/06/01
頁 數：119頁
文件格式：PDF
價 格：
USD 4,450 (Single-User License)
USD 6,250 (Global-User License)
USD 6,250 (Global-User License)
Global COVID Testing Kit Research Report—Forecast till 2027
Market Dynamics
Global COVID-19 Diagnostics Market is estimated to exhibit a CAGR of 6.28% to surpass USD 96,293.9 Million during the review period. COVID-19 is a contagious infection caused due to the coronavirus and attacks on respiratory systems. This virus is spreading rapidly hence the whole world is facing a COVID-19 pandemic. As per the research of Worldometer, there have been 4.71 million COVID-19 cases worldwide till 18 May 2020. The global market growth is propelled by the increasing number of emergency use authorizations (EUAs) for diagnostic kits & devices and developments & support by non-medical device/diagnostic companies.
Market Segmentation
Global COVID-19 Diagnostics Market has been categorized based on Type, Technology, and End Users. In terms of type segment, the global market has been divided into molecular tests and serology tests.
Based on technology type, the market has been segmented into RT-PCR, isothermal amplification, CRISPR, ELISA, hybridization, and others.
By End User segment, the COVID-19 diagnostics market has been classified into hospitals, public health labs, private or commercial labs, and others.
Regional Analysis
Geographically, the Global COVID-19 Diagnostics Market has been segmented into Europe, the Americas, Asia-Pacific, and the Middle East & Africa.
Europe contributes the largest market share of the COVID-19 diagnostics owing to the high number of infected patients in the region.
According to European Centre for Disease Control and Prevention, as of 19 May 2020, 1 317 267 cases have been reported in the European Union (EU) and European Economic Area (EEA) and the UK. Moreover, the increased COVID-19 morbidity and mortality observed among residents in long-term care facilities (LTCF) in EU/EEA countries acts as a major hurdle for disease prevention and control in such settings.
The second-largest market for COVID-19 diagnostics is estimated to be the Americas during the review period. The regional market growth is driven by the fastest outbreak of highly infectious acute respiratory disease COVID-19 and the presence of major manufacturers. Moreover, the increasing product launches by major players are also propelling the market rise during the assessment period.
Asia-Pacific is estimated to be the rapid-growing market due to the increasing number of COVID-19 cases, government & private funding for research & development for effective diagnosis during the forecast period.
The market in the Middle East & Africa is estimated to register steady growth owing to increasing COVID-19 cases and government regulations to improve patient care.
Major Players
The Prominent Players in the Global COVID-19 Diagnostics Market are Becton, Dickinson & Company (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Biomerieux SA (France), Genmark Diagnostics (US), Thermo Fisher Scientific (US), Qiagen (Germany), and Siemens AG (Germany).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Market Dynamics
Global COVID-19 Diagnostics Market is estimated to exhibit a CAGR of 6.28% to surpass USD 96,293.9 Million during the review period. COVID-19 is a contagious infection caused due to the coronavirus and attacks on respiratory systems. This virus is spreading rapidly hence the whole world is facing a COVID-19 pandemic. As per the research of Worldometer, there have been 4.71 million COVID-19 cases worldwide till 18 May 2020. The global market growth is propelled by the increasing number of emergency use authorizations (EUAs) for diagnostic kits & devices and developments & support by non-medical device/diagnostic companies.
Market Segmentation
Global COVID-19 Diagnostics Market has been categorized based on Type, Technology, and End Users. In terms of type segment, the global market has been divided into molecular tests and serology tests.
Based on technology type, the market has been segmented into RT-PCR, isothermal amplification, CRISPR, ELISA, hybridization, and others.
By End User segment, the COVID-19 diagnostics market has been classified into hospitals, public health labs, private or commercial labs, and others.
Regional Analysis
Geographically, the Global COVID-19 Diagnostics Market has been segmented into Europe, the Americas, Asia-Pacific, and the Middle East & Africa.
Europe contributes the largest market share of the COVID-19 diagnostics owing to the high number of infected patients in the region.
According to European Centre for Disease Control and Prevention, as of 19 May 2020, 1 317 267 cases have been reported in the European Union (EU) and European Economic Area (EEA) and the UK. Moreover, the increased COVID-19 morbidity and mortality observed among residents in long-term care facilities (LTCF) in EU/EEA countries acts as a major hurdle for disease prevention and control in such settings.
The second-largest market for COVID-19 diagnostics is estimated to be the Americas during the review period. The regional market growth is driven by the fastest outbreak of highly infectious acute respiratory disease COVID-19 and the presence of major manufacturers. Moreover, the increasing product launches by major players are also propelling the market rise during the assessment period.
Asia-Pacific is estimated to be the rapid-growing market due to the increasing number of COVID-19 cases, government & private funding for research & development for effective diagnosis during the forecast period.
The market in the Middle East & Africa is estimated to register steady growth owing to increasing COVID-19 cases and government regulations to improve patient care.
Major Players
The Prominent Players in the Global COVID-19 Diagnostics Market are Becton, Dickinson & Company (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Biomerieux SA (France), Genmark Diagnostics (US), Thermo Fisher Scientific (US), Qiagen (Germany), and Siemens AG (Germany).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 14
1.2 MARKET SYNOPSIS 14
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 15
2.2 RESEARCH OBJECTIVE 15
3 RESEARCH METHODOLOGY
3.1 OVERVIEW 16
3.2 DATA MINING 16
3.3 SECONDARY RESEARCH 16
3.4 PRIMARY RESEARCH 18
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING METHODS 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 21
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 22
3.8 VALIDATION 22
3.9 ASSUMPTIONS AND LIMITATIONS 23
3.9.1 ASSUMPTIONS AND LIMITATIONS 23
3.9.2 MARKET FACTORS 23
4 MARKET DYNAMICS
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 INCREASING NUMBER OF COVID-19 CASES 26
4.2.2 GOVERNMENT AND PRIVATE FUNDS AS WELL AS SUPPORT FOR RESEARCH & DEVELOPMENT 26
4.2.3 RISING NUMBER OF EMERGENCY USE AUTHORIZATIONS (EUA) FOR DIAGNOSTIC KITS AND DEVICES 26
4.2.4 DEVELOPMENTS AND SUPPORT BY NON-MEDICAL DEVICE/DIAGNOSTIC COMPANIES 27
4.3 RESTRAINTS 28
4.3.1 RESTRICTIONS ON EXPORT OF DIAGNOSTIC KITS 28
4.3.2 ACCURACY OF TEST RESULTS 28
4.4 OPPORTUNITIES 28
4.4.1 DEVELOPMENT OF QUICK, ACCURATE, AND AFFORDABLE TESTS 28
4.4.2 COLLABORATION OF MAJOR PLAYERS WITH SMALL PLAYERS 28
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 29
5.1.1 THREAT OF NEW ENTRANTS 29
5.1.2 BARGAINING POWER OF SUPPLIERS 30
5.1.3 THREAT OF SUBSTITUTES 30
5.1.4 BARGAINING POWER OF BUYERS 30
5.1.5 INTENSITY OF RIVALRY 30
5.2 SUPPLY CHAIN ANALYSIS 31
5.2.1 R&D AND DESIGNING 32
5.2.2 MANUFACTURING 32
5.2.3 DISTRIBUTION 32
5.2.4 MARKETING & SALES 32
5.2.5 POST-SALES MONITORING 32
5.3 IMPACT OF COVID-19 ON SUPPLY OF DIAGNOSTIC DEVICES 32
6 COVID-19 DIAGNOSTICS MARKET, BY TYPE
6.1 OVERVIEW 33
6.2 MOLECULAR TESTS 34
6.3 SEROLOGY TESTS 36
7 COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 OVERVIEW 38
7.2 RT-PCR 40
7.3 ISOTHERMAL AMPLIFICATION 40
7.4 CRISPR 41
7.5 ELISA 42
7.6 HYBRIDIZATION 43
7.7 OTHERS 43
8 COVID-19 DIAGNOSTICS MARKET, BY END USER
8.1 OVERVIEW 44
8.2 HOSPITALS 45
8.3 PUBLIC HEALTH LABS 46
8.4 PRIVATE OR COMMERCIAL LABS 47
9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION
9.1 OVERVIEW 48
9.2 EUROPE 50
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1 WESTERN EUROPE 52
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.1 GERMANY 53
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.2 SPAIN 54
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.3 ITALY 55
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.4 UK 56
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.5 FRANCE 57
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.6 REST OF WESTERN EUROPE 58
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.2 EASTERN EUROPE 59
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3 AMERICAS 61
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1 NORTH AMERICA 63
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1.1 US 64
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1.2 CANADA 65
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.2 LATIN AMERICA 66
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4 ASIA-PACIFIC 68
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.1 INDIA 70
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.2 AUSTRALIA 71
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.3 SOUTH KOREA 72
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.4 JAPAN 73
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.5 CHINA 74
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.6 REST OF ASIA-PACIFIC 75
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA 77
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5.1 MIDDLE EAST 79
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5.2 AFRICA 80
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 81
10.2 MAJOR PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 81
10.3 GLOBAL COVID-19 DIAGNOSTICS MARKET INSIGHTS 82
10.4 COMPETITIVE BENCHMARKING 83
10.5 COMPETITOR DASHBOARD 84
10.6 MAJOR GROWTH STRATEGIES IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 85
10.7 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 86
10.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 86
10.8.1 PRODUCT LAUNCHES 87
10.8.2 ACQUISITIONS 88
10.8.3 CONTRACTS 88
11 COMPANY PROFILES
11.1 BECTON, DICKINSON AND COMPANY 89
11.1.1 COMPANY OVERVIEW 89
11.1.2 FINANCIAL OVERVIEW 90
11.1.3 PRODUCTS/SERVICES OFFERED 90
11.1.4 KEY DEVELOPMENTS 91
11.1.5 SWOT ANALYSIS 91
11.1.6 KEY STRATEGIES 91
11.2 BIO-RAD LABORATORIES, INC. 92
11.2.1 COMPANY OVERVIEW 92
11.2.2 FINANCIAL OVERVIEW 92
11.2.3 PRODUCTS/SERVICES OFFERED 93
11.2.4 KEY DEVELOPMENTS 93
11.2.5 SWOT ANALYSIS 94
11.2.6 KEY STRATEGIES 94
11.3 DANAHER CORPORATION 95
11.3.1 COMPANY OVERVIEW 95
11.3.2 FINANCIAL OVERVIEW 96
11.3.3 PRODUCTS/SERVICES OFFERED 96
11.3.4 KEY DEVELOPMENTS 97
11.3.5 SWOT ANALYSIS 97
11.3.6 KEY STRATEGIES 97
11.4 ABBOTT 98
11.4.1 COMPANY OVERVIEW 98
11.4.2 FINANCIAL OVERVIEW 99
11.4.3 PRODUCTS/SERVICES OFFERED 99
11.4.4 KEY DEVELOPMENTS 100
11.4.5 SWOT ANALYSIS 100
11.4.6 KEY STRATEGIES 100
11.5 F. HOFFMANN-LA ROCHE LTD 101
11.5.1 COMPANY OVERVIEW 101
11.5.2 FINANCIAL OVERVIEW 102
11.5.3 PRODUCTS/SERVICES OFFERED 102
11.5.4 KEY DEVELOPMENTS 103
11.5.5 SWOT ANALYSIS 103
11.5.6 KEY STRATEGIES 103
11.6 BIOMERIEUX SA 104
11.6.1 COMPANY OVERVIEW 104
11.6.2 FINANCIAL OVERVIEW 104
11.6.3 PRODUCTS/SERVICES OFFERED 105
11.6.4 PRODUCTS/SERVICES PIPELINE 105
11.6.5 KEY DEVELOPMENTS 105
11.6.6 SWOT ANALYSIS 106
11.6.7 KEY STRATEGIES 106
11.7 GENMARK DIAGNOSTICS, INC. 107
11.7.1 COMPANY OVERVIEW 107
11.7.2 FINANCIAL OVERVIEW 107
11.7.3 PRODUCTS/SERVICES OFFERED 108
11.7.4 KEY DEVELOPMENTS 108
11.7.5 SWOT ANALYSIS 108
11.7.6 KEY STRATEGIES 108
11.8 THERMO FISHER SCIENTIFIC INC. 109
11.8.1 COMPANY OVERVIEW 109
11.8.2 FINANCIAL OVERVIEW 109
11.8.3 PRODUCTS/SERVICES OFFERED 110
11.8.4 KEY DEVELOPMENTS 110
11.8.5 SWOT ANALYSIS 110
11.8.6 KEY STRATEGIES 111
11.9 QIAGEN 112
11.9.1 COMPANY OVERVIEW 112
11.9.2 FINANCIAL OVERVIEW 113
11.9.3 PRODUCTS/SERVICES OFFERED 113
11.9.4 KEY DEVELOPMENTS 114
11.9.5 SWOT ANALYSIS 114
11.9.6 KEY STRATEGIES 114
11.10 SIEMENS AG 115
11.10.1 COMPANY OVERVIEW 115
11.10.2 FINANCIAL OVERVIEW 115
11.10.3 PRODUCTS/SERVICES OFFERED 116
11.10.4 KEY DEVELOPMENTS 116
11.10.5 SWOT ANALYSIS 116
11.10.6 KEY STRATEGIES 117
12 APPENDIX
12.1 REFERENCES 118
12.2 RELATED REPORTS 119
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 14
1.2 MARKET SYNOPSIS 14
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 15
2.2 RESEARCH OBJECTIVE 15
3 RESEARCH METHODOLOGY
3.1 OVERVIEW 16
3.2 DATA MINING 16
3.3 SECONDARY RESEARCH 16
3.4 PRIMARY RESEARCH 18
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING METHODS 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 21
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 22
3.8 VALIDATION 22
3.9 ASSUMPTIONS AND LIMITATIONS 23
3.9.1 ASSUMPTIONS AND LIMITATIONS 23
3.9.2 MARKET FACTORS 23
4 MARKET DYNAMICS
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 INCREASING NUMBER OF COVID-19 CASES 26
4.2.2 GOVERNMENT AND PRIVATE FUNDS AS WELL AS SUPPORT FOR RESEARCH & DEVELOPMENT 26
4.2.3 RISING NUMBER OF EMERGENCY USE AUTHORIZATIONS (EUA) FOR DIAGNOSTIC KITS AND DEVICES 26
4.2.4 DEVELOPMENTS AND SUPPORT BY NON-MEDICAL DEVICE/DIAGNOSTIC COMPANIES 27
4.3 RESTRAINTS 28
4.3.1 RESTRICTIONS ON EXPORT OF DIAGNOSTIC KITS 28
4.3.2 ACCURACY OF TEST RESULTS 28
4.4 OPPORTUNITIES 28
4.4.1 DEVELOPMENT OF QUICK, ACCURATE, AND AFFORDABLE TESTS 28
4.4.2 COLLABORATION OF MAJOR PLAYERS WITH SMALL PLAYERS 28
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 29
5.1.1 THREAT OF NEW ENTRANTS 29
5.1.2 BARGAINING POWER OF SUPPLIERS 30
5.1.3 THREAT OF SUBSTITUTES 30
5.1.4 BARGAINING POWER OF BUYERS 30
5.1.5 INTENSITY OF RIVALRY 30
5.2 SUPPLY CHAIN ANALYSIS 31
5.2.1 R&D AND DESIGNING 32
5.2.2 MANUFACTURING 32
5.2.3 DISTRIBUTION 32
5.2.4 MARKETING & SALES 32
5.2.5 POST-SALES MONITORING 32
5.3 IMPACT OF COVID-19 ON SUPPLY OF DIAGNOSTIC DEVICES 32
6 COVID-19 DIAGNOSTICS MARKET, BY TYPE
6.1 OVERVIEW 33
6.2 MOLECULAR TESTS 34
6.3 SEROLOGY TESTS 36
7 COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 OVERVIEW 38
7.2 RT-PCR 40
7.3 ISOTHERMAL AMPLIFICATION 40
7.4 CRISPR 41
7.5 ELISA 42
7.6 HYBRIDIZATION 43
7.7 OTHERS 43
8 COVID-19 DIAGNOSTICS MARKET, BY END USER
8.1 OVERVIEW 44
8.2 HOSPITALS 45
8.3 PUBLIC HEALTH LABS 46
8.4 PRIVATE OR COMMERCIAL LABS 47
9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION
9.1 OVERVIEW 48
9.2 EUROPE 50
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1 WESTERN EUROPE 52
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.1 GERMANY 53
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.2 SPAIN 54
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.3 ITALY 55
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.4 UK 56
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.5 FRANCE 57
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.6 REST OF WESTERN EUROPE 58
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.2 EASTERN EUROPE 59
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3 AMERICAS 61
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1 NORTH AMERICA 63
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1.1 US 64
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1.2 CANADA 65
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.2 LATIN AMERICA 66
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4 ASIA-PACIFIC 68
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.1 INDIA 70
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.2 AUSTRALIA 71
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.3 SOUTH KOREA 72
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.4 JAPAN 73
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.5 CHINA 74
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.6 REST OF ASIA-PACIFIC 75
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA 77
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5.1 MIDDLE EAST 79
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5.2 AFRICA 80
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 81
10.2 MAJOR PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 81
10.3 GLOBAL COVID-19 DIAGNOSTICS MARKET INSIGHTS 82
10.4 COMPETITIVE BENCHMARKING 83
10.5 COMPETITOR DASHBOARD 84
10.6 MAJOR GROWTH STRATEGIES IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 85
10.7 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 86
10.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 86
10.8.1 PRODUCT LAUNCHES 87
10.8.2 ACQUISITIONS 88
10.8.3 CONTRACTS 88
11 COMPANY PROFILES
11.1 BECTON, DICKINSON AND COMPANY 89
11.1.1 COMPANY OVERVIEW 89
11.1.2 FINANCIAL OVERVIEW 90
11.1.3 PRODUCTS/SERVICES OFFERED 90
11.1.4 KEY DEVELOPMENTS 91
11.1.5 SWOT ANALYSIS 91
11.1.6 KEY STRATEGIES 91
11.2 BIO-RAD LABORATORIES, INC. 92
11.2.1 COMPANY OVERVIEW 92
11.2.2 FINANCIAL OVERVIEW 92
11.2.3 PRODUCTS/SERVICES OFFERED 93
11.2.4 KEY DEVELOPMENTS 93
11.2.5 SWOT ANALYSIS 94
11.2.6 KEY STRATEGIES 94
11.3 DANAHER CORPORATION 95
11.3.1 COMPANY OVERVIEW 95
11.3.2 FINANCIAL OVERVIEW 96
11.3.3 PRODUCTS/SERVICES OFFERED 96
11.3.4 KEY DEVELOPMENTS 97
11.3.5 SWOT ANALYSIS 97
11.3.6 KEY STRATEGIES 97
11.4 ABBOTT 98
11.4.1 COMPANY OVERVIEW 98
11.4.2 FINANCIAL OVERVIEW 99
11.4.3 PRODUCTS/SERVICES OFFERED 99
11.4.4 KEY DEVELOPMENTS 100
11.4.5 SWOT ANALYSIS 100
11.4.6 KEY STRATEGIES 100
11.5 F. HOFFMANN-LA ROCHE LTD 101
11.5.1 COMPANY OVERVIEW 101
11.5.2 FINANCIAL OVERVIEW 102
11.5.3 PRODUCTS/SERVICES OFFERED 102
11.5.4 KEY DEVELOPMENTS 103
11.5.5 SWOT ANALYSIS 103
11.5.6 KEY STRATEGIES 103
11.6 BIOMERIEUX SA 104
11.6.1 COMPANY OVERVIEW 104
11.6.2 FINANCIAL OVERVIEW 104
11.6.3 PRODUCTS/SERVICES OFFERED 105
11.6.4 PRODUCTS/SERVICES PIPELINE 105
11.6.5 KEY DEVELOPMENTS 105
11.6.6 SWOT ANALYSIS 106
11.6.7 KEY STRATEGIES 106
11.7 GENMARK DIAGNOSTICS, INC. 107
11.7.1 COMPANY OVERVIEW 107
11.7.2 FINANCIAL OVERVIEW 107
11.7.3 PRODUCTS/SERVICES OFFERED 108
11.7.4 KEY DEVELOPMENTS 108
11.7.5 SWOT ANALYSIS 108
11.7.6 KEY STRATEGIES 108
11.8 THERMO FISHER SCIENTIFIC INC. 109
11.8.1 COMPANY OVERVIEW 109
11.8.2 FINANCIAL OVERVIEW 109
11.8.3 PRODUCTS/SERVICES OFFERED 110
11.8.4 KEY DEVELOPMENTS 110
11.8.5 SWOT ANALYSIS 110
11.8.6 KEY STRATEGIES 111
11.9 QIAGEN 112
11.9.1 COMPANY OVERVIEW 112
11.9.2 FINANCIAL OVERVIEW 113
11.9.3 PRODUCTS/SERVICES OFFERED 113
11.9.4 KEY DEVELOPMENTS 114
11.9.5 SWOT ANALYSIS 114
11.9.6 KEY STRATEGIES 114
11.10 SIEMENS AG 115
11.10.1 COMPANY OVERVIEW 115
11.10.2 FINANCIAL OVERVIEW 115
11.10.3 PRODUCTS/SERVICES OFFERED 116
11.10.4 KEY DEVELOPMENTS 116
11.10.5 SWOT ANALYSIS 116
11.10.6 KEY STRATEGIES 117
12 APPENDIX
12.1 REFERENCES 118
12.2 RELATED REPORTS 119
